Systematic Analysis of Adverse Event Reports for Sex Differences in Adverse Drug Events

Yue Yu, Jun Chen, Dingcheng Li, Liwei Wang, Wei Wang, Hongfang D Liu

Research output: Contribution to journalArticle

17 Citations (Scopus)

Abstract

Increasing evidence has shown that sex differences exist in Adverse Drug Events (ADEs). Identifying those sex differences in ADEs could reduce the experience of ADEs for patients and could be conducive to the development of personalized medicine. In this study, we analyzed a normalized US Food and Drug Administration Adverse Event Reporting System (FAERS). Chi-squared test was conducted to discover which treatment regimens or drugs had sex differences in adverse events. Moreover, reporting odds ratio (ROR) and P value were calculated to quantify the signals of sex differences for specific drug-event combinations. Logistic regression was applied to remove the confounding effect from the baseline sex difference of the events. We detected among 668 drugs of the most frequent 20 treatment regimens in the United States, 307 drugs have sex differences in ADEs. In addition, we identified 736 unique drug-event combinations with significant sex differences. After removing the confounding effect from the baseline sex difference of the events, there are 266 combinations remained. Drug labels or previous studies verified some of them while others warrant further investigation.

Original languageEnglish (US)
Article number24955
JournalScientific Reports
Volume6
DOIs
StatePublished - Apr 22 2016

Fingerprint

Drug-Related Side Effects and Adverse Reactions
Sex Characteristics
Drug Combinations
Pharmaceutical Preparations
Precision Medicine
Logistic Models
Odds Ratio
Food
Therapeutics

ASJC Scopus subject areas

  • General

Cite this

Systematic Analysis of Adverse Event Reports for Sex Differences in Adverse Drug Events. / Yu, Yue; Chen, Jun; Li, Dingcheng; Wang, Liwei; Wang, Wei; Liu, Hongfang D.

In: Scientific Reports, Vol. 6, 24955, 22.04.2016.

Research output: Contribution to journalArticle

@article{60eac8a30da3462a99105495e3f8159c,
title = "Systematic Analysis of Adverse Event Reports for Sex Differences in Adverse Drug Events",
abstract = "Increasing evidence has shown that sex differences exist in Adverse Drug Events (ADEs). Identifying those sex differences in ADEs could reduce the experience of ADEs for patients and could be conducive to the development of personalized medicine. In this study, we analyzed a normalized US Food and Drug Administration Adverse Event Reporting System (FAERS). Chi-squared test was conducted to discover which treatment regimens or drugs had sex differences in adverse events. Moreover, reporting odds ratio (ROR) and P value were calculated to quantify the signals of sex differences for specific drug-event combinations. Logistic regression was applied to remove the confounding effect from the baseline sex difference of the events. We detected among 668 drugs of the most frequent 20 treatment regimens in the United States, 307 drugs have sex differences in ADEs. In addition, we identified 736 unique drug-event combinations with significant sex differences. After removing the confounding effect from the baseline sex difference of the events, there are 266 combinations remained. Drug labels or previous studies verified some of them while others warrant further investigation.",
author = "Yue Yu and Jun Chen and Dingcheng Li and Liwei Wang and Wei Wang and Liu, {Hongfang D}",
year = "2016",
month = "4",
day = "22",
doi = "10.1038/srep24955",
language = "English (US)",
volume = "6",
journal = "Scientific Reports",
issn = "2045-2322",
publisher = "Nature Publishing Group",

}

TY - JOUR

T1 - Systematic Analysis of Adverse Event Reports for Sex Differences in Adverse Drug Events

AU - Yu, Yue

AU - Chen, Jun

AU - Li, Dingcheng

AU - Wang, Liwei

AU - Wang, Wei

AU - Liu, Hongfang D

PY - 2016/4/22

Y1 - 2016/4/22

N2 - Increasing evidence has shown that sex differences exist in Adverse Drug Events (ADEs). Identifying those sex differences in ADEs could reduce the experience of ADEs for patients and could be conducive to the development of personalized medicine. In this study, we analyzed a normalized US Food and Drug Administration Adverse Event Reporting System (FAERS). Chi-squared test was conducted to discover which treatment regimens or drugs had sex differences in adverse events. Moreover, reporting odds ratio (ROR) and P value were calculated to quantify the signals of sex differences for specific drug-event combinations. Logistic regression was applied to remove the confounding effect from the baseline sex difference of the events. We detected among 668 drugs of the most frequent 20 treatment regimens in the United States, 307 drugs have sex differences in ADEs. In addition, we identified 736 unique drug-event combinations with significant sex differences. After removing the confounding effect from the baseline sex difference of the events, there are 266 combinations remained. Drug labels or previous studies verified some of them while others warrant further investigation.

AB - Increasing evidence has shown that sex differences exist in Adverse Drug Events (ADEs). Identifying those sex differences in ADEs could reduce the experience of ADEs for patients and could be conducive to the development of personalized medicine. In this study, we analyzed a normalized US Food and Drug Administration Adverse Event Reporting System (FAERS). Chi-squared test was conducted to discover which treatment regimens or drugs had sex differences in adverse events. Moreover, reporting odds ratio (ROR) and P value were calculated to quantify the signals of sex differences for specific drug-event combinations. Logistic regression was applied to remove the confounding effect from the baseline sex difference of the events. We detected among 668 drugs of the most frequent 20 treatment regimens in the United States, 307 drugs have sex differences in ADEs. In addition, we identified 736 unique drug-event combinations with significant sex differences. After removing the confounding effect from the baseline sex difference of the events, there are 266 combinations remained. Drug labels or previous studies verified some of them while others warrant further investigation.

UR - http://www.scopus.com/inward/record.url?scp=84964300023&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84964300023&partnerID=8YFLogxK

U2 - 10.1038/srep24955

DO - 10.1038/srep24955

M3 - Article

VL - 6

JO - Scientific Reports

JF - Scientific Reports

SN - 2045-2322

M1 - 24955

ER -